Sirnaomics (HKG:2257) said there were no dose-limiting toxicities or serious adverse events for the second group of participants for its phase 1 study for its STP122G treatment, according to a Monday filing with the Hong Kong Stock Exchange.
The drug is indicated for patients with blood coagulation disorders, the filing said.
The study cohort employed eight participants, and the company intends to complete five cohorts of studies for a total of 40 participants.
Price (HKD): $4.05, Change: $-0.01, Percent Change: -0.25%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments